ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 505

Damage Accrual In a Single Centre Cohort Of Patients With Primary Sjögren’s Syndrome Followed Up For Over 10 Years

Chiara Baldini1, Francesco Ferro1, Pasquale Pepe2, Nicoletta Luciano1, Francesca Sernissi1, Carlotta Cacciatore1, Daniela Martini1, Antonio Tavoni3, Marta Mosca4 and Stefano Bombardieri1, 1University of Pisa, Rheumatology Unit, Pisa, Italy, 2Institute of Clinical Physiology, National Research Council, Pisa, Italy, 3University of Pisa, Immunoallergology Unit, Pisa, Italy, 4Rheumatology Unit, University of Pisa, Pisa, Italy

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Sjogren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Title: Sjögren's Syndrome: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: 1) To describe  the progression and cumulative prevalence of damage accrued over the time in a single center cohort of patients with primary Sjögren’s Syndrome (pSS) 2) to explore the influence of the patients’ clinical and serologic profile on damage accrual.

Methods: Consecutive unselected pSS patients (AECG criteria) were enrolled in this study between September 2012 and April 2013. Demographic, clinical, serologic, histological and therapeutic data of the patients enrolled were collected. Damage scores were assessed at 1, 3, 5 and 10 years post-diagnosis of pSS using both the Sjogren’s Syndrome Damage Index (SSDI) and the Sjögren’s Syndrome Disease Damage Index (SSDDI). The category/item of damage was also noted. Friedman test and Wilcoxon signed-rank test were used to evaluate damage progression over the follow-up. 

Results:

The study cohort consisted of 155 pSS patients (7M:148F; median age at diagnosis= 49 years, IQR 40-58 years; median follow-up=5 years, IQR 3-10 years). The total increase of patients with damage was 28% after 1 year, 44% after 3 years, 74% after 5 years and 83% at the end of ourstudy. Median SSDI and SSDDI total damage scores steadily increased over the 10 years from 0 (IQR 0-1) to 2 (IQR 1-4) and from 0 (IQR 0-1) to 2 (IQR 1-3), respectively, with a significant correlation between SSDI and SSDDI scores (p=0.000). The domains mainly contributing to the total damage were the oral and the ocular items. More specifically, over the follow-up, 77/155 (49.5%) patients presented teeth loss and/or caries and 53/155 (34%) showed salivary flow impairment. Persistent salivary gland swelling was detected in 22/155 patients (14%) and was associated with a lower age at pSS diagnosis (p=0.002), anti-Ro/SSA (p=0.03), cryoglobulinemia (p=0.05), low C4 (p=0.04), hypergammaglobulinemia (p=0.000) and lymphocytopenia (p=0.000). Ocular damage was observed in 35/155 patients (22.6%) with corneal ulcers in 17/155 (11%) and tear flow impairment in 31/155 subjects (20%). Systemic damage manifestations were observed in 21/155 patients (13.5%) and correlated with the ESSDAI scores at the baseline (p=0.000), low C4 levels (p=0.005) and lymphocytopenia (p=0.01). Lymphoproliferative disorders were detected in 7/155 patients (4.5%) and malignancy in 14/155 (9%) cases. 

Conclusion:

this study demonstrated that the vast majority of pSS patients developed damage within 10 years. Damage accrued mostly in the oral and ocular domains, however systemic damage manifestations and malignancy  might be observed in the 10-15% of the patients.


Disclosure:

C. Baldini,
None;

F. Ferro,
None;

P. Pepe,
None;

N. Luciano,
None;

F. Sernissi,
None;

C. Cacciatore,
None;

D. Martini,
None;

A. Tavoni,
None;

M. Mosca,
None;

S. Bombardieri,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/damage-accrual-in-a-single-centre-cohort-of-patients-with-primary-sjogrens-syndrome-followed-up-for-over-10-years/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology